Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.12

-1.4%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$929.55M
EPS-3.7200
P/E Ratio-4.07
Earnings Date08/06/2026

cgem

Total Payables

Last Annual Value

841.00K

3-Year CAGR

-51%

5-Year CAGR

-39%

10-Year CAGR

11%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Total Payables

CGEM · NASDAQ
CompanyTotal Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
841.00K
-56.7%-23.3%N/A 
75.20M
-1.2%2.4%N/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
2.84M
57.1%N/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
9.20M
-16.5%-11.7%N/A
5.41M
-18.7%-12.6%3.1%
3.38M
115.6%15.6%N/A
36.27M
91.4%78.5%N/A
5.91M
-8.5%-15.5%8.9%
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.125, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.125